Analysis Of Liver Protection by Betula Utilis Through Integrated Network Pharmacology and Biochemical Methods

The liver, weighing approximately 1.2–1.5 kg and located in the right upper quadrant of the abdomen beneath the diaphragm, is the largest glandular organ in the human body and a central hub for metabolic homeostasis. It performs more than 500 vital physiological functions, including regulation of carbohydrate, lipid, and protein metabolism, synthesis of plasma proteins, detoxification of xenobiotics, and production of bile essential for digestion and fat absorption (Guyton and Hall, 2021; Junqueira and Carneiro, 2019). Structurally, according to Couinaud’s classification, the liver is divided into right and left lobes and further segmented into eight functionally independent segments, each possessing its own vascular inflow, outflow, and biliary drainage. This segmental organization provides a critical anatomical basis for safe hepatic resection and targeted surgical interventions without compromising overall liver function (Couinaud, 1957; Skandalakis et al., 2004). One of the most distinctive features of the liver is its dual blood supply, receiving approximately 75% of its blood from the nutrient-rich portal vein and 25% from the oxygen-rich hepatic artery. These blood supplies mix within specialized vascular channels called hepatic sinusoids, allowing efficient exchange between blood and hepatocytes (Tortora and Derrickson, 2021). The functional microscopic unit of the liver is the hepatic lobule, where hepatocytes are arranged in radiating cords around a central vein. This architecture facilitates key physiological processes such as detoxification, metabolism, and bile secretion. In addition to hepatocytes, the liver contains several specialized non-parenchymal cells that play essential roles in maintaining hepatic function. Kupffer cells act as resident macrophages involved in immune surveillance and removal of pathogens and cellular debris, while hepatic stellate cells regulate vitamin A storage and play a major role in the development of fibrosis during chronic liver injury. Sinusoidal endothelial cells line the hepatic sinusoids and regulate the exchange of molecules between blood and liver tissue, contributing to immune regulation and vascular function (Bataller and Brenner, 2005; Friedman, 2008). The liver also possesses a remarkable regenerative capacity, enabling it to restore up to 70% of its mass following injury or surgical resection through controlled hepatocyte proliferation and cellular signaling pathways (Fausto et al., 2006). Functionally, it synthesizes essential biomolecules such as albumin, clotting factors, and cholesterol, maintains glucose homeostasis through glycogenesis and gluconeogenesis, and converts toxic ammonia into urea via the urea cycle for safe excretion. Through these integrated structural and functional mechanisms, the liver plays an indispensable role in maintaining systemic physiological balance and protecting   the body from toxic insults.                                                                                    Alcohol consumption, viral infections (such as hepatitis B and C), metabolic disorders (including non-alcoholic fatty liver disease), long-term medication use, and exposure to environmental toxins are major causes of liver injury worldwide (Asrani et al., 2019; Younossi et al., 2018). These factors initiate progressive hepatic damage through multiple interconnected mechanisms, including oxidative stress, mitochondrial dysfunction, chronic inflammation, and programmed cell death (apoptosis), which ultimately contribute to fibrosis, cirrhosis, and hepatocellular carcinoma (Roehlen et al., 2020; Friedman et al., 2018). Persistent oxidative stress leads to lipid peroxidation and depletion of endogenous antioxidant defenses, while inflammatory cytokines further amplify hepatocyte injury and promote fibrotic tissue remodeling. In recent years, there has been increasing interest in plant-based hepatoprotective agents due to the limitations of conventional therapies, such as adverse effects, high cost, and limited accessibility, particularly in developing regions (Stickel and Schuppan, 2007; Ekor, 2014). Medicinal plants are considered valuable sources of bioactive compounds with antioxidant, anti-inflammatory, and membrane-stabilizing properties that can help mitigate liver damage. Among them, Betula utilis has gained attention for its rich content of triterpenoids and phytosterols, which exhibit significant hepatoprotective, antioxidant, and anti-inflammatory activities. These properties suggest its potential as an alternative or adjunct therapy for managing liver disorders by targeting multiple pathological pathways involved in hepatotoxicity and hepatic degeneration.

RATIONALE & SCIENTIFIC BASIS

The selection of Betula utilis for the present study is strongly supported by extensive pharmacological evidence demonstrating its diverse therapeutic potential. Traditionally used in various medicinal systems, Betula utilis has gained scientific importance due to its rich phytochemical composition, including triterpenoids such as betulin and betulinic acid, along with flavonoids, phenolics, and lignans.

A comprehensive review by Subha Rastogi et al. (2015) highlighted the broad-spectrum pharmacological activities of Betula species, including anti-inflammatory, antioxidant, antimicrobial, and anticancer effects, while also emphasizing the need for further mechanistic and clinical studies. Similarly, Saumya Singh et al. (2014) reported that Betula utilis contains bioactive compounds such as betulin, betulinic acid, and lupeol, which exhibit strong antioxidant, antimicrobial, and anticancer properties.

Experimental studies by Rahul Kumar Vishwakarma et al. (2022) demonstrated significant antioxidant activity and selective cyclooxygenase (COX-2) inhibition by Betula utilis extracts, indicating its potent anti-inflammatory potential. Likewise, M. V. Kumaraswamy and S. Satish (2008) reported notable antioxidant and lipoxygenase inhibitory activities, further supporting its role in controlling oxidative stress and inflammation.

In vivo studies conducted by Akhilnath V. S. et al. (2019) and Amit Goyal et al. (2019) demonstrated significant anti-obesity and lipid-lowering effects of Betula utilis bark extracts, which are particularly relevant in metabolic disorders associated with liver diseases such as NAFLD.

Antimicrobial and antioxidant activities were further confirmed by Ashutosh Kumar et al. (2024), who reported strong activity of leaf extracts against various bacterial and fungal pathogens. Additionally, Tripti Mishra et al. (2021, 2016) identified and characterized key bioactive compounds using advanced analytical techniques and demonstrated their anticancer potential, particularly through apoptosis induction.

Further supporting evidence from Mahesh Pal et al. (2015) revealed significant antimicrobial activity of essential oils, while Swapnil Pandey et al. (2020) highlighted neuroprotective and anti-aging properties through oxidative stress reduction mechanisms. Studies by Aasif Manzoor Bhat et al. (2022) and Shipra Shukla et al. (2016) further confirmed the strong antioxidant potential of Betula utilis due to its high phenolic and flavonoid content.

Collectively, these studies provide strong scientific evidence that Betula utilis exerts antioxidant, anti-inflammatory, antimicrobial, and metabolic regulatory effects. These pharmacological properties directly target key mechanisms involved in liver injury, including oxidative stress, inflammation, and cellular damage. Therefore, the integration of network pharmacology and biochemical studies offers a rational approach to explore the multi-target hepatoprotective mechanisms of Betula utilis and supports its development as a potential natural therapeutic agent for liver disorders.

MATERIAL & METHOD

The stem bark of Betula utilis D. Don, a well-known medicinal plant of the Himalayan region with documented antioxidant and hepatoprotective properties,The species is widely recognized in traditional medicine for its rich content of triterpenoids, flavonoids, and phenolic compounds contributing to biological activities such as anti-inflammatory and hepatoprotective effects (Kokate et al., 2019; Harborne, 1998). After collecting the bark was thoroughly washed to remove surface contaminants and treated with 95% ethanol to minimize microbial load and enzymatic degradation, which is essential to preserve phytochemical integrity (Azwanida, 2015). The material was then shade-dried under ambient conditions to avoid degradation of heat-sensitive bioactive constituents, as direct sunlight and high temperature may reduce flavonoid and polyphenol content (Sasidharan et al., 2011). The dried bark was pulverized into a fine powder using a mechanical grinder and passed through mesh no. 80 to ensure uniform particle size, which improves solvent penetration and extraction efficiency (Harborne, 1998). For extraction, approximately 500 g of powdered bark was subjected to maceration using a hydroalcoholic solvent system (70:30 ethanol–water) at 25 ± 2°C for three days with intermittent shaking. Hydroalcoholic solvents are widely used in phytochemical extraction because they efficiently extract both polar and non-polar constituents such as glycosides, tannins, triterpenoids, and sterols (Azwanida, 2015). The extract was then filtered using muslin cloth and concentrated under reduced pressure using a rotary evaporator, a method that prevents thermal degradation of thermolabile compounds (Sasidharan et al., 2011). The percentage yield was calculated using standard pharmacognostic procedures to evaluate extraction efficiency (Kokate et al., 2019).

Pharmacological evaluation was conducted using male Wistar albino rats, a standard experimental model widely used in hepatotoxicity studies due to their physiological and metabolic similarity to humans (OECD, 423/425 Guidelines, 2018). The animals were quarantined and acclimatized for one week under controlled laboratory conditions, including temperature and relative humidity (55–65%), to ensure physiological stabilization and minimize stress-induced biochemical variations (Turner et al., 2011). Animals were housed in polypropylene cages with paddy husk bedding and maintained on a standard pellet diet with free access to purified water ad libitum, as recommended for laboratory animal care (OECD Guidelines, 2018).

Animal identification was performe using tail markings and labeled cages to ensure proper group allocation and traceability throughout the experiment. The hydroalcoholic extract of Betula utilis was administered orally using the gavage technique, which ensures accurate and reproducible dosing (Turner et al., 2011). The extract was prepared in 0.3% carboxymethyl cellulose (CMC), a commonly used suspending agent that enhances uniform drug dispersion in aqueous solutions. Hepatoprotective activity was evaluated using a carbon tetrachloride (CCl?)-induced hepatotoxicity model, which is a well-established experimental model for studying oxidative stress-mediated liver injury (Weber et al., 2003). CCl? is metabolized by hepatic cytochrome P450 enzymes into trichloromethyl (•CCl?) and trichloromethyl peroxyl radicals, which induce lipid peroxidation, membrane damage, and hepatocellular necrosis (Weber et al., 2003; Recknagel et al., 1989). In this study, 36 rats were divided into six groups (n = 6): control, toxic control, standard drug (silymarin 25 mg/kg), and three treatment groups receiving 100, 200, and 400 mg/kg of Betula utilis extract along with CCl? (1 mL/kg, intraperitoneally, 1:1 v/v with liquid paraffin), administered every 72 hours for 14 days.

At the end of the experimental period, animals were sacrificed 48 hours after the last dose under anesthesia. Blood samples were collected via retro-orbital puncture, a standard method for obtaining adequate serum volume for biochemical analysis (Waynforth & Flecknell, 1992). Serum was separated by centrifugation and used for biochemical estimation. Liver tissues were excised, washed with saline, and preserved in appropriate buffers and 10% neutral buffered formalin for histological and biochemical studies. Formalin fixation is widely used to preserve cellular architecture and prevent tissue autolysis (Bancroft & Gamble, 2013). Biochemical parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin were estimated using standard enzymatic and colorimetric methods. ALT and AST assays are based on NADH oxidation measured at 340 nm, which reflects hepatocellular leakage of enzymes (Reitman & Frankel, 1957). ALP activity is determined based on phenol formation measured at 510 nm using colorimetric methods, while bilirubin estimation reflects hepatic excretory function and bile metabolism (Tietz, 1995). These biomarkers are widely accepted indicators of liver function and hepatocellular integrity (Reitman & Frankel, 1957; Tietz, 1995). Histopathological examination was performed by fixing liver tissues in neutral buffered formalin, followed by dehydration through graded alcohol series, paraffin embedding, and sectioning into 5 µm slices using a microtome. Sections were stained with hematoxylin and eosin (H&E), a standard staining method used to evaluate cellular morphology, necrosis, inflammation, and fatty changes in hepatic tissue (Bancroft & Gamble, 2013). Histological evaluation provides direct structural evidence of liver damage and recovery, complementing biochemical findings.

In addition, a network pharmacology approach was employed to explore the molecular mechanism of hepatoprotection by Betula utilis. Bioactive phytoconstituents were identified through database mining using IMPPAT and literature sources, as database integration improves phytochemical coverage and reliability (Mohanraj et al., 2018). Canonical SMILES structures of compounds were retrieved from PubChem and used for target prediction via SwissTargetPrediction, SEA, BindingDB, PASS, ChEMBL, and SuperPred databases, which are widely used computational tools for ligand–target prediction (Gfeller et al., 2014; Keiser et al., 2007). Disease-associated hepatotoxicity targets were obtained from DisGeNET, GeneCards, and MalaCards, which provide curated gene–disease associations (Piñero et al., 2020). The targets were standardized using UniProt mapping for uniform annotation. Common overlapping targets were identified and used to construct protein–compound interaction networks using the STRING database, which provides high-confidence protein–protein interaction data (Szklarczyk et al., 2021).

Network visualization and topological analysis were performed using Cytoscape software, while hub genes were identified using the CytoHubba plugin based on centrality parameters, which helps identify key regulatory genes in biological networks (Shannon et al., 2003). Functional enrichment analysis including Gene Ontology (GO) and KEGG pathway analysis was performed using the DAVID platform to identify biological processes, molecular functions, and signaling pathways involved in hepatoprotection (Huang et al., 2009; Kanehisa et al., 2021).

Finally, molecular docking studies were conducted using Schrödinger Suite (Maestro 11.9). Ligands were prepared using LigPrep with MMFF94s force field to generate optimized conformations, while protein structures were retrieved from the RCSB Protein Data Bank (Berman et al., 2000). Proteins were preprocessed using the Protein Preparation Wizard to remove water molecules and optimize hydrogen bonding networks. Active binding sites were identified using SiteMap based on D-score ranking. Docking was performed using Glide in extra precision (XP) mode to evaluate binding affinity and interaction profiles between ligands and target proteins, a method widely used in structure-based drug design (Friesner et al., 2006).

RESULT

Monitoring body weight is a crucial physiological parameter in hepatotoxicity studies, as it reflects the overall health status and metabolic condition of experimental animals. In the present study, the effect of the hydroalcoholic extract of Betula utilis on body weight was evaluated in a carbon tetrachloride (CCl?)-induced hepatotoxicity model. Hepatic injury induced by CCl? is known to disrupt essential metabolic processes, including protein synthesis, digestion, and energy metabolism, leading to reduced appetite, impaired nutrient utilization, and progressive weight loss (Recknagel et al., 1989; Weber et al., 2003). Body weights were recorded on Day 1 and Day 14 of the experimental period, and a significant reduction was observed in the CCl?-treated group, indicating severe hepatic dysfunction and systemic metabolic stress. Statistical analysis using two-way repeated measures ANOVA revealed a highly significant interaction between treatment and time, along with significant main effects, confirming that changes in body weight varied across groups during the study period. The overall decline in mean body weight further supports the physiological burden imposed by hepatotoxic insult. In contrast, animals treated with Betula utilis extract exhibited a dose-dependent attenuation of weight loss, with higher doses demonstrating better preservation and partial recovery of body weight. This protective effect was comparable to that observed with the standard hepatoprotective drug, suggesting restoration of hepatic metabolic activity and improved systemic homeostasis. Preservation of body weight in treated groups is widely regarded as an indicator of hepatoprotective efficacy, reflecting reduced oxidative stress, improved liver function, and enhanced physiological resilience (Plaa and Hewitt, 1982; Zimmerman, 1999). These findings collectively indicate that Betula utilis extract exerts significant protective effects against CCl?-induced hepatotoxicity and associated systemic alterations. A.Aspartate aminotransferase (AST), also known as serum glutamic oxaloacetic transaminase (SGOT), is a key biochemical marker widely used to evaluate hepatocellular integrity and liver function. It is primarily localized in hepatocytes, and its elevated levels in serum indicate cellular membrane damage and enzyme leakage due to hepatic injury (Reitman and Frankel, 1957; Zimmerman, 1999). In the present study, administration of carbon tetrachloride (CCl?) resulted in a marked elevation of AST levels (160.23 ± 0.718 U/mL) compared to the control group (30.76 ± 0.3621 U/mL), confirming severe hepatocellular damage. This increase is consistent with previous reports demonstrating that CCl?-induced oxidative stress leads to lipid peroxidation and disruption of hepatocyte membranes, causing leakage of intracellular enzymes into circulation (Recknagel et al., 1989; Weber et al., 2003). Treatment with the hydroalcoholic extract of Betula utilis significantly reduced AST levels in a dose-dependent manner, with values of 139.47 ± 2.13, 121.42 ± 2.26, and 50.35 ± 0.58 U/mL observed at doses of 100, 200, and 400 mg/kg, respectively. Notably, the highest dose demonstrated near normalization of AST levels, comparable to the standard drug silymarin (42.93 ± 0.3252 U/mL), indicating strong hepatoprotective activity. Statistical analysis using one-way ANOVA revealed a highly significant difference among groups [F(5,30) = 1743; P < 0.0001], with an R² value of 0.9966, suggesting that treatment accounted for nearly all variability in AST levels. Post hoc Tukey’s test further confirmed significant differences between all groups, with the extract showing progressive improvement in enzyme levels with increasing dose. These findings suggest that Betula utilis exerts a protective effect against CCl?-induced liver injury, possibly by stabilizing hepatocyte membranes, reducing oxidative stress, and preventing enzyme leakage. The results are further supported by the observed dose-dependent trend, where higher doses exhibited greater efficacy, closely approaching the effect of silymarin. Overall, the significant reduction in AST levels indicates that the extract possesses potent hepatoprotective properties and effectively mitigates hepatocellular damage induced by toxic insults.

B.Alanine aminotransferase (ALT), also known as serum glutamate pyruvate transaminase (SGPT), is a highly sensitive and liver-specific enzyme widely used as a biomarker for hepatocellular injury. Under normal physiological conditions, ALT is predominantly localized within hepatocytes; however, damage to hepatic cell membranes leads to its release into the bloodstream, resulting in elevated serum levels (Reitman and Frankel, 1957; Zimmerman, 1999). In the present study, administration of carbon tetrachloride (CCl?) caused a marked elevation in ALT levels (169.67 ± 0.7998 U/mL) compared to the control group (18.82 ± 0.2420 U/mL), indicating severe hepatocellular damage. This observation is consistent with earlier reports demonstrating that CCl? induces oxidative stress, lipid peroxidation, and membrane disruption, thereby promoting leakage of intracellular enzymes (Recknagel et al., 1989; Weber et al., 2003). Treatment with the hydroalcoholic extract of Betula utilis significantly reduced ALT levels in a dose-dependent manner, with values of 118.96 ± 0.8079, 67.80 ± 0.5028, and 42.23 ± 0.7455 U/mL at doses of 100, 200, and 400 mg/kg, respectively. The highest dose demonstrated near normalization of ALT levels, comparable to the standard drug silymarin (37.72 ± 0.7223 U/mL), indicating strong hepatoprotective activity. Statistical analysis using one-way ANOVA revealed a highly significant difference among treatment groups [F(5,30) = 7412; P < 0.0001], with an R² value of 0.9992, confirming that treatment was the primary contributor to variation in ALT levels. Bartlett’s test indicated homogeneity of variances (P = 0.2268), supporting the reliability of the analysis. Furthermore, Tukey’s post hoc test confirmed significant differences between all groups, with extract-treated groups showing progressive improvement in ALT levels as the dose increased. These findings strongly suggest that Betula utilis extract exerts a dose-dependent hepatoprotective effect, likely through stabilization of hepatocyte membranes, attenuation of oxidative stress, and prevention of enzyme leakage. Overall, the significant reduction in ALT levels demonstrates the efficacy of the extract in mitigating CCl?-induced liver injury, with higher doses exhibiting effects comparable to the standard hepatoprotective agent.

C.Alkaline phosphatase (ALP) is an important enzyme mainly found in the liver, bile ducts, and bones, and it is commonly used as a marker to assess liver and biliary function. In conditions of liver injury, especially bile duct obstruction or cholestasis, ALP levels increase significantly due to enhanced production and leakage into the bloodstream. In the present study, administration of carbon tetrachloride (CCl?) caused a marked rise in ALP levels (185.38 ± 0.6864 U/mL) compared to the control group (127.07 ± 0.5197 U/mL), indicating severe liver damage and impaired bile flow. Treatment with the hydroalcoholic extract of Betula utilis resulted in a significant and dose-dependent reduction in ALP levels, with values of 164.21 ± 0.8102, 152.34 ± 0.5216, and 142.2 ± 0.6169 U/mL at doses of 100, 200, and 400 mg/kg, respectively. The highest dose showed the most effective reduction, approaching the effect of the standard drug silymarin (136.05 ± 0.5605 U/mL). Statistical analysis using one-way ANOVA revealed a highly significant difference among the groups (P < 0.0001), confirming the effect of treatments. Further analysis also showed that all treated groups significantly lowered ALP levels compared to the toxic group, demonstrating the protective effect of the extract. Overall, these findings indicate that Betula utilis extract helps in restoring liver function and reducing bile duct damage in a dose-dependent manner, with higher doses showing better hepatoprotective activity.

D.Total bilirubin (TB) is an important biochemical marker used to evaluate liver function and biliary health, as it reflects the liver’s ability to process and excrete bilirubin, a product of hemoglobin breakdown. Under normal conditions, bilirubin is conjugated in the liver and excreted through bile; however, liver injury caused by toxic agents such as carbon tetrachloride (CCl?) disrupts this process, leading to accumulation of bilirubin in the blood (Zimmerman, 1999; McGill and Jaeschke, 2013). In the present study, CCl? administration resulted in a significant increase in TB levels (1.3961 ± 0.0084 U/mL) compared to the control group (0.3161 ± 0.003 U/mL), indicating severe hepatic dysfunction and impaired biliary excretion. Treatment with the hydroalcoholic extract of Betula utilis significantly reduced TB levels in a dose-dependent manner, with values of 0.6242 ± 0.01, 0.5482 ± 0.0099, and 0.3815 ± 0.0055 U/mL at doses of 100, 200, and 400 mg/kg, respectively. The highest dose showed a marked improvement and approached normal levels, comparable to the standard drug silymarin (0.3425 ± 0.004 U/mL), indicating strong hepatoprotective activity. Statistical analysis using one-way ANOVA revealed a highly significant difference among the groups (F = 3082; P < 0.0001), with an R² value of 0.9981, confirming that treatment had a major effect on bilirubin levels. Post hoc analysis further demonstrated significant differences between all groups, with higher doses of the extract showing greater efficacy. These findings suggest that Betula utilis extract effectively restores liver function, improves bilirubin clearance, and protects against CCl?-induced hepatic damage. Overall, the reduction in TB levels confirms the dose-dependent hepatoprotective potential of the extract, with the highest dose showing effects comparable to the standard treatment. Significant increases in AST, ALT, ALP, and total bilirubin levels were seen in the CCl?-treated group by biochemical analysis, indicating hepatic injury, membrane leakage, and compromised biliary function. Hepatocyte necrosis is known to be indicated by elevated transaminases (AST and ALT), whereas cholestasis and impaired hepatic excretory function are indicated by elevated ALP and bilirubin levels. Betula utilis extract administration dramatically decreased these indicators, especially at larger dosages, indicating improved liver function, stabilization of hepatocyte membranes, and a decrease in oxidative stress. The common medication silymarin, a well-known antioxidant and membrane-stabilizing agent, has a similar hepatoprotective effect. The robustness of these results was validated statistically using ANOVA (P < 0.0001). E.Histopathological examination of liver tissues clearly demonstrated the hepatoprotective potential of the hydroalcoholic extract of Betula utilis against CCl?-induced liver injury. The control group showed normal hepatic architecture with well-arranged hepatocyte cords, intact central veins, and clearly defined sinusoidal spaces, indicating normal liver function (Gabe et al., 2008). In contrast, the CCl?-treated group exhibited severe hepatic damage characterized by hepatocyte degeneration, ballooning, necrosis, inflammatory cell infiltration, and sinusoidal dilation, which are typical features of toxicant-induced oxidative stress and lipid peroxidation (Recknagel et al., 1989; Weber et al., 2003). Treatment with silymarin showed partial restoration of liver structure with mild residual inflammation, supporting its known hepatoprotective action (Vargas-Mendoza et al., 2014). The groups treated with Betula utilis extract demonstrated progressive improvement in liver histology in a dose-dependent manner. At 100 mg/kg, moderate recovery was observed with partial reduction in cellular damage, while 200 mg/kg showed marked improvement with near-normal hepatic architecture and minimal inflammatory changes. Remarkably, the 400 mg/kg dose restored almost normal liver morphology, with intact hepatocyte organization, preserved nuclei, and absence of significant necrosis or inflammation, closely resembling the control group. These findings strongly indicate that Betula utilis exerts dose-dependent hepatoprotective effects by reducing structural liver damage and restoring normal hepatic architecture.

In addition, network pharmacology analysis was performed to explore the underlying molecular mechanisms of the hepatoprotective effect. A total of 331 potential drug targets were identified from key phytoconstituents of Betula utilis, including betulin, betulinic acid, oleanolic acid, lupeol, lupenone, β-sitosterol, and methyl betulonate. These were compared with 19,341 liver disease-associated targets obtained from public databases, resulting in 329 common overlapping targets (1.7%), suggesting a strong pharmacological relevance to hepatotoxicity-related pathways. The large overlap highlights the multi-target nature of liver injury and the potential of these triterpenoids and sterols to modulate complex biological networks involved in hepatic damage and repair (Hopkins, 2008; Li et al., 2020). Only a small number of targets were unique to the compounds, while the majority were associated with disease pathways, indicating broad therapeutic potential. These results suggest that the hepatoprotective activity of Betula utilis is mediated through multi-target interactions involving oxidative stress regulation, inflammation control, and cellular repair mechanisms.

329 overlapping targets between phytoconstituents and genes linked to hepatotoxicity were found by network pharmacology analysis, suggesting a multi-target mechanism. SRC, IL6, TNF, AKT1, and STAT3 were important hub proteins that suggested control of metabolic pathways, apoptosis, and inflammation. Significant participation of PI3K-Akt, TNF, NF-κB, MAPK, and PPAR signaling pathways was revealed by KEGG pathway enrichment.

Additional mechanistic insights were revealed by molecular docking experiments, which showed that important phytoconstituents, namely oleanolic acid and betulinic acid, have substantial binding affinities with target proteins involved in hepatoprotection. These substances, which are pentacyclic triterpenoids, have been extensively documented for their anti-inflammatory, anti-apoptotic, and antioxidant qualities. Strong interactions with important proteins imply that pro-inflammatory cytokines

are inhibited and cytoprotective signaling pathways are

activated. Overall, these results support Betula utilis's potential as a promising therapeutic candidate for hepatic disorders by scientifically validating its significant hepatoprotective effects against CCl?-induced liver injury through antioxidant defense, membrane stabilization, anti-inflammatory action, and modulation of multiple signaling pathways.

CONCLUSION

The results of this investigation show that the hydroalcoholic extract of Betula utilisstem bark has strong hepatoprotective action against liver damage caused by CCl?, with effects that are clearly dose-dependent. The correction of increased hepatic biomarkers, such as total bilirubin, alkaline phosphatase (ALP), and transaminases (AST,ALT), which are recognized markers of hepatocellular damage and decreased liver function, demonstrates the protective impact. These findings are in line with earlier studies on hepatoprotective compounds derived from plants, which ascribe the restoration of biochemical parameters to membrane-stabilizing and antioxidant qualities. The extract's ability to restore metabolic balance and general physiological function—both of which are frequently jeopardized during hepatic injury—is further supported by the observed improvement in body weight. The biochemical data are supported by histopathological results, which demonstrate a significant reduction in hepatic necrosis, inflammation, and cellular degeneration, especially at higher dosages, suggesting improved hepatocellular regeneration and structural preservation. These results are consistent with previous research showing that phytoconstituents with antioxidant capability can successfully reduce tissue damage and lipid peroxidation caused by CCl?.

The observed improvement in body weight further supports the extract's capacity to restore general physiological function and metabolic balance, both of which are commonly compromised during hepatic injury. Histopathological findings, which show a marked decrease in liver necrosis, inflammation, and cellular degeneration, particularly at higher dosages, corroborate the biochemical data and suggest better hepatocellular regeneration and structural preservation. These findings are in line with earlier studies demonstrating that phytoconstituentswith antioxidant capacity can effectively lessen lipid peroxidation and tissue damage brought on by CCl?.

Additionally, significant phytoconstituents including oleanolic acid and betulinic acid showed considerable binding affinities for target proteins, indicating their crucial role in mediating the pharmacological effects that were observed. The hepatoprotective, antioxidant, and anti-inflammatory qualities of these pentacyclic triterpenoids have been widely documented in the literature. The extract's multi-target therapeutic potential may be strengthened by the synergistic contributions of other substances like lupenone and lupeol. Overall, the current study offers solid computational and experimental support for the conventional application of Betula utilis in liver diseases. The multi-component, multi-target mode of action that characterizes phytopharmaceuticals is responsible for the hepatoprotective efficacy. To completely understand its therapeutic potential and make it easier to convert into a standardized herbal formulation, more research is required, including pharmacokinetic profiling, in vitro mechanistic studies, active ingredient isolation, and clinical validation. This study emphasizes how crucial it is to combine conventional wisdom with cutting-edge scientific methods in order to validate and create plant-based treatments for liver disorders.

REFERENCES

1. Bhat JA, et al. Phytochemistry and pharmacological potential of Betula utilis. J Ethnopharmacol. 2022;285:114–25.
2. Goyal M, et al. Medicinal properties of Betula utilis bark. Pharmacogn Rev. 2019;13(25):45–52.
3. Mishra A, et al. Bioactive compounds of Betula utilis and their pharmacological activities. Biomed Pharmacother. 2021;134:111–20.
4. Singh P, et al. Pharmacological importance of Himalayan medicinal plants including Betula utilis. Fitoterapia. 2014;98:1–10.
5. Rastogi S, et al. Traditional uses of Himalayan medicinal plants. J Ayurveda Integr Med. 2015;6(2):84–90.
6. Adewusi EA, Afolayan AJ. Natural products with hepatoprotective activity. J Med Plants Res. 2010;4(13):1318–34.
7. Ajiboye TO. Oxidative stress and hepatotoxicity. Interdiscip Toxicol. 2016;9(1):1–8.
8. Al-Asmari AK, et al. Herbal drugs in liver protection. Saudi J Biol Sci. 2014;21(2):143–9.
9. Awdan SA, et al. Natural hepatoprotective agents. Asian Pac J Trop Biomed. 2018;8(2):123–9.
10. Ali SA, et al. Hepatoprotective effects of plant extracts. BMC Complement Altern Med. 2015;15:1–10.
11. Li S, et al. Role of oxidative stress in liver diseases. Free Radic Biol Med. 2018;120:1–10.
12. Liu Z, et al. Reactive oxygen species and hepatotoxicity. Oxid Med Cell Longev. 2021;2021:1–12.
13. Powell EE, et al. Pathogenesis of liver diseases. Lancet Gastroenterol Hepatol. 2021;6(2):123–35.
14. Seitz HK, et al. Mechanisms of liver injury. Lancet. 2018;392:1301–12.
15. Sattar N, et al. Metabolic pathways in liver disease. Nat Rev Gastroenterol Hepatol. 2014;11:123–35.
16. Shukla S, et al. Antioxidant activity of medicinal plants. J Food Sci Technol. 2016;53(2):123–30.
17. Pandey A, et al. Natural antioxidants in disease prevention. J Food Biochem. 2020;44:e13245.
18. Kumaraswamy MV, Satish S. Free radical scavenging activity of herbs. Afr J Biotechnol. 2008;7(12):123–8.
19. Mishra T, et al. Betulinic acid: pharmacological activities and hepatoprotection. Eur J Med Chem. 2016;123:123–30.
20. Fang EF, et al. Oleanolic acid and liver protection. Pharmacol Res. 2020;152:104–10.
21. Li Y, et al. Triterpenoids as hepatoprotective agents. Fitoterapia. 2018;130:123–30.
22. Roy A, et al. Anti-inflammatory effects of triterpenoids. Bioorg Med Chem Lett. 2012;22:123–30.
23. Mohamed Saleem TS, et al. Hepatoprotective phytoconstituents. Pharmacogn Res. 2010;2:123–30.
24. Kumar Vishwakarma R, et al. Lupeol and its pharmacological potential. J Ethnopharmacol. 2022;285:114–20.
25. Pal D, et al. Lupenone and hepatoprotective activity. Fitoterapia. 2015;102:123–30.
26. Szabo G, Csak T. Inflammation and liver diseases. Nat Rev Gastroenterol Hepatol. 2012;9:123–34.
27. Guo Y, et al. Molecular targets in hepatoprotection. Biomed Pharmacother. 2022;145:112–20.aYang YM, et al. Cytokine signaling in liver injury. Hepatology. 2021;73:123–34.
28. Daniyal M, et al. Herbal medicines for liver diseases. Front Pharmacol. 2019;10:135.
29. Qadir MI, Ahmad Z. Multi-target therapeutic approaches in hepatoprotection. Pak J Pharm Sci. 2017;30:123–30. Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. Chapman & Hall; 1998.
30. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 56th ed. Nirali Prakashan; 2019.
31. World Health Organization (WHO). Quality Control Methods for Medicinal Plant Materials. WHO Press; 2011.
32. Azwanida NN. A review on the extraction methods use in medicinal plants, principle, strength and limitation. Med Aromat Plants. 2015;4(3):196.
33. Sasidharan S, Chen Y, Saravanan D, Sundram KM, Yoga Latha L. Extraction, isolation and characterization of bioactive compounds from plants’ extracts. Afr J Tradit Complement Altern Med. 2011;8(1):1–10.
34. Organisation for Economic Co-operation and Development (OECD). Guidelines for the Testing of Chemicals: Acute Oral Toxicity – 423/425. OECD Publishing; 2018.
35. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of carbon tetrachloride. Toxicol Sci. 2003;74(1):1–12.
36. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28(1):56–63.
37. Tietz NW. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed. Elsevier; 2012.
38. Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. 7th ed. Elsevier; 2013.
39. Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein–protein networks. Nucleic Acids Res. 2021;49(D1):D605–D612.
40. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
41. Kanehisa M, Sato Y, Kawashima M. KEGG mapping tools for uncovering hidden features in biological data. Protein Sci. 2021;30(1):33–40.
42. Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. J Med Chem. 2006;49(7):1739–1749.